KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
45 hedge funds and large institutions have $42.5M invested in KalVista Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
10% more funds holding
Funds holding: 41 → 45 (+4)
0.54% more ownership
Funds ownership: 44.71% → 45.25% (+0.54%)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
49% less capital invested
Capital invested by funds: $84.1M → $42.5M (-$41.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$597K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$460K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$385K |
| 4 |
PVI
Pura Vida Investments
New York
|
+$244K |
| 5 |
MC
Menta Capital
San Francisco,
California
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$674K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$469K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$280K |
| 4 |
Goldman Sachs
New York
|
-$179K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$144K |
KALV Hedge Fund Activity: Q3 2015 in Review
45 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2015, worth a combined $42.5M — down 49% from $84.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KALV positions and 4 closed out — a net gain of 4 holders — while 14 added to existing stakes and 16 trimmed.
The largest buyer was Northern Trust, adding an estimated $597K. The largest seller was Pentwater Capital Management, cutting an estimated $674K.
- 45 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2015, up from 41 in Q2 2015.
- Funds reported $42.5M of KalVista Pharmaceuticals stock for Q3 2015, down 49% quarter-over-quarter.
- 8 funds opened new KalVista Pharmaceuticals positions in Q3 2015 and 4 closed out, a net change of +4 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2015 was Northern Trust, an estimated $597K added.
- The largest KalVista Pharmaceuticals seller in Q3 2015 was Pentwater Capital Management, an estimated $674K sold.
Based on aggregated 13F filings for Q3 2015.